Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23

NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343

Read More

Other news Stine Krag Brunvold 5/9/23 Other news Stine Krag Brunvold 5/9/23

NMD Pharma to Attend Bio€quity Europe 2023

Read More

Other news Stine Krag Brunvold 3/7/23 Other news Stine Krag Brunvold 3/7/23

We will be in Basel for BIO-Europe Spring

Read More

Events Stine Krag Brunvold 2/28/23 Events Stine Krag Brunvold 2/28/23

Rare Disease Day, 28 February 2023

Read More

Other news Stine Krag Brunvold 1/4/23 Other news Stine Krag Brunvold 1/4/23

Meet us at J.P. Morgan Healthcare Conference on January 9-12, 2023 in San Francisco

Read More

Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

Read More

Press release Stine Krag Brunvold 12/14/22 Press release Stine Krag Brunvold 12/14/22

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

Read More

Other news Stine Krag Brunvold 12/7/22 Other news Stine Krag Brunvold 12/7/22

Thomas Holm Pedersen, will be participating in the 7th Annual Nordic American Life Science Conference

Read More

Other news Stine Krag Brunvold 12/3/22 Other news Stine Krag Brunvold 12/3/22

Today is International Day of Persons with Disabilities

Read More

Other news Stine Krag Brunvold 11/24/22 Other news Stine Krag Brunvold 11/24/22

We have been awarded Entrepreneur of the Year in the Life Sciences category by EY Denmark!

Read More

Other news Stine Krag Brunvold 11/24/22 Other news Stine Krag Brunvold 11/24/22

NMD Pharma will be at the Life Science Career Fair Aarhus 22

Read More

Other news Stine Krag Brunvold 10/24/22 Other news Stine Krag Brunvold 10/24/22

NMD Pharma is attending BIO Europe

Read More

Events Stine Krag Brunvold 10/11/22 Events Stine Krag Brunvold 10/11/22

Today we are able to announce positive topline data from our Phase I/IIa clinical trial of NMD670 in patients with Myasthenia Gravis

Read More

Press release Stine Krag Brunvold 10/11/22 Press release Stine Krag Brunvold 10/11/22

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis

Read More

Other news Stine Krag Brunvold 9/30/22 Other news Stine Krag Brunvold 9/30/22

Thomas Holm Pedersen speaks at The First Nordic Conference on Myasthenia Gravis

Read More

Press release Stine Krag Brunvold 9/27/22 Press release Stine Krag Brunvold 9/27/22

FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis

Read More

Other news Stine Krag Brunvold 9/16/22 Other news Stine Krag Brunvold 9/16/22

Thomas Holm Pedersen speaks at The Global CMT Research Convention

Read More

Other news Stine Krag Brunvold 9/7/22 Other news Stine Krag Brunvold 9/7/22

The INCUBA Awards

Read More

Other news Stine Krag Brunvold 9/6/22 Other news Stine Krag Brunvold 9/6/22

NMD Pharma will be at LSX Nordic Congress

Read More

Other news Stine Krag Brunvold 9/1/22 Other news Stine Krag Brunvold 9/1/22

CMT Awareness Month in the US

Read More